Logo

Genome-based Personalized Medicine

Aug 20, 2008

James Watson and Craig Venter might both be Caucasian men, but according to their genes, Watson would metabolize drugs differently than Venter, writes a group led by Venter in Clinical Pharmacology and Therapeutics. The group analyzed six drug-metabolizing genes, including the CYP genes, and found that Venter is an extensive metabolizer and Watson is an intermediate metabolizer with an allele that is rare in Caucasians. "Race-based medicine doesn't have any real basis in science," says Venter in the New Scientist.

Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.